Therefore, HDAC6 inhibition selectively promoted apoptosis of cells with ARID1A mutation, but not ARID1A wildtype, as verified by the improved survival of ARID1A-deficient tumor-bearing mice upon treatment of a clinically applicable small molecule inhibitor of HDAC6 [69]. The gene discussed is HDAC6; the disease is neoplasm.